Article
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Neoplasia (New York, N.Y.) - 1 Jan 2018
Zhang Cathy C, Yan Zhengming, Pascual Bernadette, Jackson-Fisher Amy, Huang Donghui Stephen, Zong Qing, Elliott Mark, Fan Conglin, Huser Nanni, Lee Joseph, Sung Matthew, Sapra Puja
Abstract excerpt
Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-drug conjugate for the treatment of acute myeloid leukemia (AML). Although GO shows a narrow therapeutic window in early clinical studies, recent reports detailing a modified dosing regimen of GO can be safely combined with induction chemotherapy, and the combination provides significant survival benefits in AML patients. Here we tested whether the survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.